Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

Avanos Medical announced it will be acquired by American Industrial Partners in an all-cash deal valued at $1.272 billion. Stockholders will receive $25.00 per share, representing a 72.1% premium over the previous closing price. The deal, unanimously approved by the board, is expected to close in the second half of 2026. The announcement comes after Avanos beat earnings expectations with Q4 adjusted EPS of 29 cents versus 25 cents consensus, and sales of $180.9 million versus $174.7 million expected.

Avanos Medical reported Q2 2025 financial results, highlighting strong performance in Specialty Nutrition Systems and Pain Management segments, while divesting its hyaluronic acid product line. The company maintained full-year revenue and earnings guidance despite tariff challenges and leadership changes.

The report provides a comprehensive analysis of the United States market for syringes, needles, and urinary catheters, including market data, company profiles, and industry trends from 2018 to 2033.

The global bio pharma buffer market is expected to grow from $1.1 billion in 2023 to $2.4 billion by 2033, driven by the rising demand for biopharmaceuticals and the need for high-quality buffers in drug development and manufacturing.

The global pain management devices market is projected to grow at a CAGR of 21.5% from 2024 to 2031, driven by the increasing prevalence of chronic diseases and the rising demand for non-invasive pain management solutions.

Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

Avanos Medical (AVNS) delivered earnings and revenue surprises of +4.76% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) delivered earnings and revenue surprises of -9.52% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?